From St. Paul, Minnesota, USA:
My 10 year old son was diagnosed with type 1 diabetes three weeks ago, so I am scrambling to learn all I can about the disease. He has just entered his honeymoon period. As I understand it, the remaining 10% or so of his beta cells have been in "shock" from the load trying to keep up the levels and have not been producing insulin. With the help of the insulin shots they have now "recovered" and started producing insulin again. What causes this to end? Are they eventually destroyed by his immune system? Were they still being attacked while they were not producing insulin?
We don't know very much about the honeymoon period. It does not have to happen at all, especially in the very youngest patients (i.e., preschoolers). Good glucose control seems to help start and sustain the honeymoon period anecdotally. We do not know exactly what ends the honeymoon phase but the autoimmune attack likely continues to destroy any remaining beta cells over subsequent weeks and months. While we can turn off this autoimmune attack in some animal models with strong immunosuppressant drugs, this is still too risky for human use except in experimental situations. Future research is looking to get safer immunosuppression or figure out some other way to stop this autoimmune attack.
[Editor's comment: This site has probably all the information you'll ever need. Take time looking through it and spend some time in the Chat Rooms to talk to parents and kids who have "been there". SS]
Original posting 7 Oct 2002
Posted to Honeymoon
Last Updated: Tuesday April 06, 2010 15:09:38
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2016. Comments and Feedback.